<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04645173</url>
  </required_header>
  <id_info>
    <org_study_id>CPR-2214</org_study_id>
    <nct_id>NCT04645173</nct_id>
  </id_info>
  <brief_title>Comparison of Participants Who Received a CanGaroo® Envelope, Tyrx™ Envelope, or no Envelope During CIED Implantation</brief_title>
  <acronym>HEAL</acronym>
  <official_title>A Multi-Center Study Evaluating Participants Who Received CanGaroo® Envelope, Tyrx™ Envelope, or No Envelope During CIED Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziyo Biologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aziyo Biologics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to gather information on participants returning at time of&#xD;
      CIED change-out or revision who underwent a device implantation with either a CanGaroo®&#xD;
      envelope, Tyrx™ envelope, or no envelope.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center study will enroll up to approximately 100 participants who originally&#xD;
      underwent implantation of a CIED with either CanGaroo®, Tyrx™, or no envelope (up to&#xD;
      approximately 30-35 participants per cohort) and are returning for a CIED change-out or&#xD;
      revision procedure at least 12 months or longer from their prior procedure.&#xD;
&#xD;
      Once enrolled, each participant will have their medical history data collected (baseline&#xD;
      demographics, medical history, prior CIED exchanges/revisions, and post implant clinical&#xD;
      events). Prior to the scheduled change-out/revision procedure, there will be an assessment of&#xD;
      the current healed implant site skin incision independently by both the participant and&#xD;
      investigator using the Patient and Observer Scar Assessment Scale (POSAS), as well as&#xD;
      photographs taken of the current skin scar.&#xD;
&#xD;
      During the change-out/revision procedure, additional investigator assessments will include&#xD;
      photographic documentation of CIED implant pocket lining, classification of the extent of&#xD;
      lead adhesions in the implant pocket, and biopsies of the anterior and posterior capsule&#xD;
      walls for histologic analysis. Procedural details and any complications/AEs that occur during&#xD;
      the change-out/revision procedure will also be captured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blinded Histologic Evaluation of Biopsies Taken from the Anterior and Posterior Capsule Wall</measure>
    <time_frame>Surgical Procedure Visit</time_frame>
    <description>Microscopic analysis of cellularity, vascularity, collagen density, necrosis, infectious agents, remnant device material, giant cells, and fibrotic capsule thickness will be evaluated for each biopsy site using a quantitative scoring system with an attempt to distinguish between remnant envelope collagen (if ECM envelope was used) and neocollagen from the participant. Composite (total) and average scores will be determined based on the individual scores from each biopsy site. The quantitative thickness of each fibrotic capsule biopsy will be measured using digital image software. Four (4) thickness measurements will be performed across the image for each biopsy sample, and the average fibrotic thickness will be reported for each sample. In addition, the total average thickness across the four samples will be determined based on the average individual recordings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Documented CIED Complications</measure>
    <time_frame>Pre-Surgery Visit</time_frame>
    <description>Comparison between cohorts of documented clinical outcomes and complications since the most recent CIED procedure through the current change-out/revision procedure. Assessment of the clinical outcomes &amp; events of the 3 cohorts will inform on potential differences in clinical outcomes that may be related to the cohort treatment. For example: infection, Twiddler's syndrome, CIED migration, CIED erosion, lead revision, lead dislodgement, pocket revision, device reprogramming, pocket revision.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient and Observer Scar Assessment Scale (POSAS)</measure>
    <time_frame>Pre-Surgery Visit</time_frame>
    <description>10-point score: Each item of the POSAS is rated on a 10-point score. The lowest score is '1', which corresponds to the situation of normal skin (i.e., normal pigmentation, no itching). Score 10 equals the largest difference from normal skin (i.e., the worst imaginable scar or sensation).&#xD;
Total score: The total score of both scales can be simply calculated by summing up the scores of each of the six items. The total score can range from 6 to 60. The overall opinion item is not included in the sum score.</description>
  </other_outcome>
  <other_outcome>
    <measure>CIED Scar Photographs</measure>
    <time_frame>Pre-Surgery Visit</time_frame>
    <description>Comparison of photographs of the previous skin incision scar taken pre-surgery. The visual differences in the skin incision scar appearance between the 3 cohorts may correlate with histologic findings and/or post-implant clinical outcomes or events.</description>
  </other_outcome>
  <other_outcome>
    <measure>CIED Implant Photographs</measure>
    <time_frame>Surgical Procedure Visit</time_frame>
    <description>Comparison of photographs of the previous CIED implant pocket interior taken intraoperatively. The visual differences in interior capsule wall appearance between the 3 cohorts may correlate with histologic findings and/or post-implant clinical outcomes or events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Lead Adhesions within the Implant Pocket</measure>
    <time_frame>Surgical Procedure Visit</time_frame>
    <description>This observation should be made while the CIED device is mobilized and removed from within the implant pocket.&#xD;
The classification system is based on two estimated factors:&#xD;
The amount of fibrosis by visual estimate (none/trivial, mild, moderate, or severe).&#xD;
NOTE: If calcification is present, the capsule should be classified as Class 3 (severe).&#xD;
The estimate of the percentage of the lead coiled within the implant pocket that is adhered or trapped within the capsule wall (Class 0: none, Class 1: &lt;30%, Class 2: 30%-60%, and Class 3: &gt;60%).</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiac Disease</condition>
  <arm_group>
    <arm_group_label>CanGaroo Envelope</arm_group_label>
    <description>Participants who received a CanGaroo envelope during CIED implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tyrx Envelope</arm_group_label>
    <description>Participants who received a Tyrx envelope during CIED implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Envelope</arm_group_label>
    <description>Participants who did not receive an envelope during CIED implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CIED envelope</intervention_name>
    <description>Evaluation of the difference in cohorts for soft tissue healing surrounding the CIED implant and clinical outcomes and complications.</description>
    <arm_group_label>CanGaroo Envelope</arm_group_label>
    <arm_group_label>Tyrx Envelope</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Characteristics of soft tissue healing surrounding CIED implant as assessed by blinded&#xD;
      histologic evaluation of systematic biopsies taken at the time of change-out/revision.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who underwent one prior CIED implantation procedure at the current implant&#xD;
        site utilizing CanGaroo®, Tyrx™, or no envelope and are returning for a CIED change-out or&#xD;
        revision procedure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants who previously underwent a CIED implantation utilizing a CanGaroo®&#xD;
             envelope, Tyrx™ envelope, or no envelope and are returning for a CIED change-out or&#xD;
             revision procedure at least 12 months or longer from their prior procedure.&#xD;
&#xD;
          2. Participants who only had one prior CIED implantation procedure at the current implant&#xD;
             site (Participants with more than one prior CIED implantation involving sites other&#xD;
             than the current site can be included, provided the current implant was the first&#xD;
             implant procedure at the site for the present change-out or revision procedure).&#xD;
&#xD;
          3. Participants aged 18 years or older at time of enrollment.&#xD;
&#xD;
          4. Participant is able and agrees to provide written informed consent and use of PHI.&#xD;
&#xD;
          5. Participants for whom prior CIED implant history information can be obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active infection involving the CIED implant site (clinical diagnosis of an active&#xD;
             infection at the time of change-out/revision procedure).&#xD;
&#xD;
          2. Participants under the age of 18 at time of enrollment.&#xD;
&#xD;
          3. Participants who have had more than one prior CIED implantation procedure at the&#xD;
             current site.&#xD;
&#xD;
          4. Participants undergoing a change-out or revision procedure less than 12 months from&#xD;
             their prior procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephanie Richardson</last_name>
    <phone>678-492-4712</phone>
    <email>srichardson@aziyo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joel Eggebeen</last_name>
    <email>jeggebeen@aziyo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Valley Heart Rhythm Specialists</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Brackin</last_name>
      <phone>480-534-7308</phone>
      <email>elballiet@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Gianani Cabrera</last_name>
      <phone>480-534-7308</phone>
      <email>gpcabrera26@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Huy Phan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bay Pines VA</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cortny Withee</last_name>
      <email>cortny.withee@va.gov</email>
    </contact>
    <investigator>
      <last_name>Afolabi Sangosanya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pamela Debus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystal Cedeno</last_name>
      <email>krystal.cedeno@bmcjax.com</email>
    </contact>
    <contact_backup>
      <last_name>Doran Cassidy</last_name>
      <email>doran.cassidy@bmcjax.com</email>
    </contact_backup>
    <investigator>
      <last_name>Aaditya Vora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Austin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Rhodes</last_name>
      <email>Elizabeth.Rhodes@jax.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Burton</last_name>
      <email>Andrea.Burton@jax.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Catanzaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edin Sadic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Education &amp; Research Cooperative / St. John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Bainter</last_name>
      <phone>217-492-9100</phone>
      <phone_ext>29142</phone_ext>
      <email>lbainter@prairieresearch.com</email>
    </contact>
    <investigator>
      <last_name>Ziad Issa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Shen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bharath Rajagopalan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Mullin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suresh Kulandhaisamy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U of L Health/Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Copeland</last_name>
      <email>stephanie.copeland@uoflhealth.org</email>
    </contact>
    <investigator>
      <last_name>Rajdeep Gaitonde, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Dalton</last_name>
      <email>keb2114@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Treena Williams</last_name>
      <email>taw2112@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hirad Yarmohammadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elaine Wan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Waase, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angelo Biviano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Dizon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederick Ehlert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoffrey Rubin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amardeep Saluja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Patterson</last_name>
      <email>janet.patterson@atriumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Michele Esposito</last_name>
      <email>michele.esposito@atriumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Christopher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sherry Saxonhouse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University/Vidant Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bremer</last_name>
      <email>BREMERJ17@ECU.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Eddie Hill, MPH</last_name>
      <email>hille19@ecu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rajasekhar Nekkanti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aditi Naniwadekar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Shoemaker</last_name>
      <email>katie.shoemaker@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin D'Souza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Medical Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hollis Phillips</last_name>
      <email>hp9r@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Bilchick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oliver Monfredi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pamela Mason, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rohit Malhotra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mike Mangrum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Darby, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aziyo.com</url>
    <description>Aziyo Biologics, Inc.</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

